Is AOD-9604 Legal in Arizona?

What AOD-9604 Actually Is

AOD-9604 is a synthetic 16-amino-acid fragment corresponding to positions 177 through 191 on the C-terminal end of human growth hormone (hGH). Researchers originally isolated it because the lipolytic activity of hGH appears concentrated in that region, while the diabetogenic effects are associated with other parts of the molecule.

The GRAS Designation and What It Does (and Does Not) Mean

In 2004, the FDA granted AOD-9604 Generally Recognized as Safe (GRAS) status specifically for its proposed use as an oral food additive, under the trade name Tregopil at the time of early research. That designation covered one narrow oral application. It did not authorize injectable formulations, and it did not constitute drug approval under 21 U.S.C. § 355 [1].

Telehealth marketers sometimes cite the GRAS notice as proof of broad federal approval. That reading is incorrect. GRAS status and new drug approval are separate regulatory tracks, and injectable AOD-9604 has never cleared the latter.

Why the Injectable Form Matters Clinically

Weight management and body composition are the primary clinical rationales for prescribing AOD-9604. A 2000 study published in the journal Obesity Research (now Obesity) found that AOD-9604 reduced adiposity in obese Zucker rats without producing the insulin resistance associated with full-length hGH [2]. Human phase II data from Metabolic Pharmaceuticals showed modest but measurable reductions in body fat, though the company halted its phase III program in 2007 after interim results did not meet endpoints for statistically significant weight loss in the broader enrolled population.

The compound has not completed a successful phase III randomized controlled trial in humans. That gap is the single most consequential fact for understanding its regulatory position.

Federal Legal Framework: FDA Rules That Apply in Every State

The 503A Compounding Pathway

Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) allows licensed pharmacists to compound drugs for individual patients when a valid prescription exists, the drug is not commercially available in adequate strength or form, and the compound is not made from a bulk ingredient the FDA has identified as presenting safety concerns [3].

The FDA publishes and periodically updates a list of bulk drug substances that may be used in 503A compounding (the "positive list" or "Category 1" list) and a list of substances that may not be used because they raise safety concerns or lack adequate clinical evidence. AOD-9604 was placed on the FDA's list of bulk drug substances that present demonstrable compounding risks in 2023, effectively restricting its use in 503A traditional compounding pharmacies [4].

That restriction is not a criminal ban on the molecule itself. It is a restriction on the compounding pathway most outpatient pharmacies use.

The 503B Outsourcing Facility Pathway

Section 503B of the FDCA created a separate category: registered outsourcing facilities that can compound larger volumes without patient-specific prescriptions, provided they meet current good manufacturing practice (cGMP) standards and comply with FDA oversight [3]. AOD-9604 faces the same clinical evidence requirements under the 503B framework. The FDA evaluates whether a substance is appropriate for 503B compounding based on clinical need, safety, and effectiveness data, and the bar is high for a compound that failed phase III.

As of the date this article was reviewed, AOD-9604 does not appear on the FDA's approved 503B bulk drug substance list either.

Research Use vs. Clinical Use

AOD-9604 may lawfully be manufactured and sold as a research chemical for use in laboratory or animal studies, provided the seller does not make disease treatment claims and does not intend it for human consumption [5]. Many online vendors sell it under that label. Purchasing such products for self-injection falls outside this exemption, violates FDA regulations, and creates real safety risks because these products are not manufactured under pharmaceutical-grade quality controls.

Arizona State Law: What the State Adds (and What It Leaves to Federal Rules)

Arizona Board of Pharmacy Standards

Arizona's pharmacy practice is governed by Title 32, Chapter 18 of the Arizona Revised Statutes and the rules promulgated by the Arizona State Board of Pharmacy (AZSBP). Arizona does not have a separate state statute that independently classifies AOD-9604 as either permitted or prohibited. The state board's compounding rules generally track federal 503A and 503B standards, meaning the FDA's 2023 restrictions on AOD-9604 in traditional compounding carry direct practical weight for Arizona-licensed pharmacies [6].

A pharmacy that compounds AOD-9604 for individual patients under a physician's order is operating in a legally ambiguous space because of the FDA bulk-drug restriction. Pharmacists in Arizona who compound a restricted bulk substance face potential action from both the FDA and the AZSBP.

Arizona Medical Practice Act and Prescriber Authority

Under Arizona Revised Statutes § 32-1401 et seq., licensed physicians (MD and DO) have broad authority to prescribe treatments they judge medically appropriate, including off-label uses of lawfully available compounds. That authority does not override FDA compounding restrictions. A physician can write a prescription for AOD-9604, but if no compliant pharmacy can legally fill it under current federal rules, the prescription has limited practical effect through standard outpatient channels.

Some clinics argue they are dispensing AOD-9604 under the physician-dispensing provisions of Arizona law. That interpretation carries regulatory risk and should be evaluated by a health law attorney before a clinic proceeds on that basis.

Controlled Substance Classification in Arizona

AOD-9604 is not listed in the DEA's schedules I through V, and Arizona's controlled substances schedules (Arizona Revised Statutes § 36-2512 through § 36-2516) do not independently list it. Possession of AOD-9604 is therefore not a criminal drug offense analogous to possessing a scheduled narcotic or stimulant. The regulatory risk is civil and administrative, not criminal, for patients who obtain it through gray-market sources. Clinics or pharmacies that dispense it in violation of federal compounding rules face FDA enforcement, not criminal drug charges under the Controlled Substances Act.

The 2023 FDA Bulk-Drug Restriction: A Closer Look

The practical impact of the 2023 FDA restriction depends on which compounding category a pharmacy operates under. The table below summarizes the three-layer framework:

| Pathway | Who Uses It | AOD-9604 Status (2025) | |---|---|---| | 503A Traditional Compounding | Retail and specialty pharmacies | Restricted; bulk substance not on positive list | | 503B Outsourcing Facility | High-volume compounders, hospital systems | Not on approved bulk list; compounding not authorized | | Physician-Office Dispensing | Some physician clinics | Subject to state medical practice act; federal risk remains | | Research-Grade Purchase | Laboratories, academic researchers | Lawful if no human-use claims are made |

The FDA's guidance on bulk drug substances for compounding is published on the agency's dedicated compounding page [4]. Stakeholders submitted comments during the rulemaking period arguing that AOD-9604's GRAS status and early phase II human safety data justified inclusion on the positive list. The FDA did not accept those arguments for the injectable form.

The Endocrine Society's clinical practice guidelines on obesity pharmacotherapy, updated in 2023, list approved GLP-1 receptor agonists (liraglutide 3 mg and semaglutide 2.4 mg) and the GIP/GLP-1 agonist tirzepatide as first-line agents for weight management, noting that evidence thresholds for recommending any agent require phase III trial completion [7]. AOD-9604 does not meet that threshold.

As the FDA states in its compounding policy documentation: "FDA has determined that the bulk drug substances identified on the 503A Bulks List may be used by licensed pharmacists in the compounding of drug products... Substances not on that list are not eligible for use unless they meet specific criteria." [4]

How to Get AOD-9604 in Arizona Legally

What a Compliant Pathway Looks Like

A compliant access pathway requires, at minimum:

• A valid patient-physician relationship established through an in-person or synchronous telemedicine evaluation.
• A licensed Arizona physician (MD or DO) who has documented a clinical rationale.
• A dispensing source that has conducted its own regulatory review and can demonstrate compliance with applicable federal and state rules.

Given the FDA's 2023 restriction on 503A compounding, any clinic or pharmacy currently dispensing AOD-9604 in Arizona should be prepared to explain the specific legal basis on which it is operating. Patients should ask that question directly.

Telehealth Prescribing in Arizona

Arizona is a member of the Interstate Medical Licensure Compact and has broadly permissive telehealth laws following the post-2020 regulatory environment. A physician licensed in Arizona can prescribe through a synchronous video visit. The prescription itself is lawful. The bottleneck is the pharmacy's ability to compound or dispense the product under current federal rules, not the prescriber's authority to write the order.

What to Avoid

• Unregulated online vendors marketing AOD-9604 as a "research peptide" for human use. These products are not manufactured under cGMP, carry contamination risks, and purchasing them for self-injection puts the buyer outside any legal protection.
• Clinics that claim AOD-9604 is "fully FDA approved" based on the 2004 GRAS designation. That claim misrepresents the regulatory record.
• Purchasing internationally marketed formulations and importing them for personal use. The FDA's personal importation policy does not routinely cover unapproved new drugs, and injectable formulations of unverified peptides carry serious sterility risks [5].

Comparing AOD-9604 to Approved Weight-Loss Agents

Patients who are exploring AOD-9604 for weight management should understand where it sits relative to approved alternatives. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001) [8]. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 20.9% mean weight reduction at 72 weeks versus 3.1% with placebo (P<0.001) [9].

AOD-9604's phase II data, by contrast, showed modest fat-mass reductions in the range of 1 to 2 kg over 12 weeks in some dosing arms, with the phase III program discontinued before efficacy was confirmed in a large randomized trial.

The weight-loss effect size comparison is stark. Patients and clinicians choosing between an unproven compounded peptide with regulatory restrictions and an FDA-approved agent with phase III outcome data should have that comparison on the table.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital and a past president of the Obesity Society, has written that "the bar for recommending any weight-loss agent must include demonstration of efficacy and safety in adequately powered clinical trials" [7]. AOD-9604 has not crossed that bar for injectable use in humans.

Risks of the Current Gray-Market Supply Chain

Because compliant compounding channels are restricted, some of the AOD-9604 circulating in clinical practice comes from sources operating outside standard pharmaceutical oversight. A 2018 analysis published in JAMA Internal Medicine examined 44 compounded peptide products and found that 25 (56.8%) contained less than 90% of the labeled active ingredient, and 23 (52.3%) failed sterility testing [10]. That study predates the specific 2023 AOD-9604 restriction but illustrates the quality-control problem with peptides sourced outside regulated pharmacy channels.

Subcutaneous injection of a non-sterile product carries risks of local infection, abscess formation, and systemic bacteremia. These are not theoretical risks.

What Arizona Patients Should Ask a Prescriber

Before accepting a prescription for AOD-9604 in Arizona, a patient should ask:

1. Which specific pharmacy will fill this prescription, and can you provide documentation of that pharmacy's regulatory compliance?
2. Is the pharmacy a 503A or 503B facility, and how does it address the FDA's 2023 bulk-drug restriction?
3. What is the documented clinical rationale in my medical record?
4. Has the clinic's legal counsel reviewed the dispensing arrangement under current FDA guidance?

These questions are not adversarial. They are the minimum due diligence for any compounded injectable medication.